Skip to main content
BPH ENERGY LTD logo

BPH ENERGY LTD — Investor Relations & Filings

Ticker · BPH ISIN · AU000000BPH4 ASX Financial and insurance activities
Open in API
Filings indexed 1,483 across all filing types
Latest filing 2009-11-22 Proxy Solicitation & In…
Country AU Australia
Listing ASX BPH

About BPH ENERGY LTD

https://www.bphenergy.com.au/

BPH Energy Ltd is a diversified investment company focused on the commercialization of biomedical technologies and the exploration of energy resources. The company maintains a significant portfolio in the biotechnology sector, notably through its investment in Cortical Dynamics Ltd, which develops the Brain Anaesthesia Response Monitor (BARM) for objective measurement of anesthetic effect. In the energy sector, BPH Energy holds a substantial interest in Advent Energy Ltd, an unlisted oil and gas exploration company with assets including the PEP 11 permit in the offshore Sydney Basin. Additionally, the company has expanded its focus into sustainable energy through investments in Clean Hydrogen Technologies, which utilizes proprietary processes to produce turquoise hydrogen and solid carbon. BPH Energy aims to identify and develop high-growth opportunities within the healthcare and resource sectors to create long-term value.

Recent filings

Filing Released Lang Actions
Notice of General Meeting/Proxy Form 76 pages ?Kb
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'NOTICE OF GENERAL MEETING' and includes detailed information about the time, place, agenda, and resolutions to be voted on at a shareholder meeting. It contains a proxy form, explanatory statements, and schedules related to the meeting. The content focuses on shareholder voting matters such as change of company name, capital reduction, asset acquisition, share and option placements, and director options issuance. There is no financial data or earnings information presented, nor is it a transcript or presentation. The document is clearly a notice and explanatory material for a general meeting, which fits the category of Proxy Solicitation & Information Statement (PSI).
2009-11-22 English
Notice of Annual General Meeting/Proxy Form 8 pages ?Kb
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting' and includes details about the time, date, and place of the AGM. It contains the agenda for the meeting, including resolutions to be voted on, such as the adoption of the remuneration report and the re-election of a director. It also includes proxy voting instructions and an explanatory statement related to the AGM. There is no actual financial data or full report content; rather, it is a notice and explanatory material for the shareholders to prepare for the AGM. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document is not an Annual Report or Remuneration Information report itself, but a notice and explanatory statement for the AGM.
2009-11-22 English
Hls5 Presentation 51st ASH Annual Meeting 2 pages ?Kb
Investor Presentation Classification · 90% confidence The document is an ASX announcement from BioPharmica Limited dated 20 November 2009. It announces that Dr. Louise Winteringham will present at the 51st ASH Annual Meeting on 7 December 2009. The content includes a detailed abstract of the scientific research related to Hls5, a novel ubiquitin E3 ligase, and its role in hematopoietic lineage commitment. The document is primarily an announcement of a presentation at a scientific conference, not a financial report, regulatory filing, or management update. It does not contain financial data, voting results, or corporate governance information. The document is best classified as an Investor Presentation (IP) because it provides detailed information about the company's scientific research and strategic development related to its product pipeline, which is typical content for investor presentations aimed at informing shareholders and potential investors about company progress and prospects.
2009-11-19 English
NHMRC $608,500 Grant for HLS5 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from BioPharmica Limited dated 13 November 2009. It announces a grant awarded by the National Health and Medical Research Council (NHMRC) and details a planned spin-off of a company called Molecular Discovery Systems. The content is an update on a grant and corporate restructuring plans, including shareholder information about receiving shares in the spin-off company. There are no financial statements, earnings data, or detailed financial analysis present. The document is relatively short (2416 characters) and serves as a corporate announcement rather than a full report or financial filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update. It is not a regulatory certification or voting result. The best fit is a general Regulatory Filing (RNS) as it is a regulatory announcement that does not fit other specific categories.
2009-11-12 English
BioPharmica Limited - 2009 Annual General Meeting Update 1
AGM Information Classification · 90% confidence The document is a short letter dated 10 November 2009 addressed to shareholders providing an update on the date of the 2009 Annual General Meeting (AGM). It mentions that the Notice of Meeting has been lodged and that the company is awaiting approval and an extension for the meeting date. The document does not contain the AGM materials themselves, nor does it include financial data or detailed reports. It is an announcement about the scheduling and regulatory status of the AGM, not the AGM presentation or the Annual Report. The document length is only 1189 characters, which is very short and consistent with an announcement rather than a full report. Therefore, this fits best as an AGM Information update or announcement. However, since it is an update on the AGM date and not the AGM materials themselves, it is best classified as AGM Information (AGM-R) as it relates directly to the AGM event and its scheduling.
2009-11-09 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, reconciliation of cash, and notes on accounting standards. The report covers a specific quarter ended 30 September 2009, indicating it is a periodic financial report shorter than a full fiscal year. The presence of actual financial statements and substantive financial data confirms it is a financial report rather than an announcement or certification. Appendix 4C is a known quarterly cash flow report format used in Australian regulatory filings, which aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q1 2010
2009-10-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.